RESEARCH ARTICLE　　　　　　　　　　　　　　　　　　　　　　**Open Access**

CrossMark

Chemokine receptor co-expression reveals aberrantly distributed T_H effector memory cells in GPA patients

Lucas L. Lintermans[1], Abraham Rutgers[1], Coen A. Stegeman[2], Peter Heeringa[3] and Wayel H. Abdulahad[1,3*]

Abstract

Background: Persistent expansion of circulating $CD4^+$ effector memory T cells (T_{EM}) in patients with granulomatosis with polyangiitis (GPA) suggests their fundamental role in disease pathogenesis. Recent studies have shown that distinct functional $CD4^+$ T_{EM} cell subsets can be identified based on expression patterns of chemokine receptors. The current study aimed to determine different $CD4^+$ T_{EM} cell subsets based on chemokine receptor expression in peripheral blood of GPA patients. Identification of particular circulating $CD4^+$ T_{EM} cells subsets may reveal distinct contributions of specific $CD4^+$ T_{EM} subsets to the disease pathogenesis in GPA.

Method: Peripheral blood of 63 GPA patients in remission and 42 age- and sex-matched healthy controls was stained immediately after blood withdrawal with fluorochrome-conjugated antibodies for cell surface markers (CD3, CD4, CD45RO) and chemokine receptors (CCR4, CCR6, CCR7, CRTh2, CXCR3) followed by flow cytometry analysis. $CD4^+$ T_{EM} memory cells ($CD3^+CD4^+CD45RO^+CCR7^-$) were gated, and the expression patterns of chemokine receptors $CXCR3^+CCR4^-CCR6^-CRTh2^-$, $CXCR3^-CCR4^+CCR6^-CRTh2^+$, $CXCR3^-CCR4^+CCR6^+CRTh2^-$, and $CXCR3^+CCR4^-CCR6^+CRTh2^-$ were used to distinguish $T_{EM}1$, $T_{EM}2$, $T_{EM}17$, and $T_{EM}17.1$ cells, respectively.

Results: The percentage of $CD4^+$ T_{EM} cells was significantly increased in GPA patients in remission compared to HCs. Chemokine receptor co-expression analysis within the $CD4^+$ T_{EM} cell population demonstrated a significant increase in the proportion of $T_{EM}17$ cells with a concomitant significant decrease in the $T_{EM}1$ cells in GPA patients compared to HC. The percentage of $T_{EM}17$ cells correlated negatively with $T_{EM}1$ cells in GPA patients. Moreover, the circulating proportion of $T_{EM}17$ cells showed a positive correlation with the number of organs involved and an association with the tendency to relapse in GPA patients. Interestingly, the aberrant distribution of $T_{EM}1$ and $T_{EM}17$ cells is modulated in CMV- seropositive GPA patients.

Conclusions: Our data demonstrates the identification of different $CD4^+$ T_{EM} cell subsets in peripheral blood of GPA patients based on chemokine receptor co-expression analysis. The aberrant balance between $T_{EM}1$ and $T_{EM}17$ cells in remission GPA patients, showed to be associated with disease pathogenesis in relation to organ involvement, and tendency to relapse.

Keywords: Vasculitis, Granulomatosis with polyangiitis, T_H cells, Effector memory T_H cells, Chemokine receptors

* Correspondence: w.abdulahad@umcg.nl
[1]Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
[3]Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
Full list of author information is available at the end of the article

Lintermans *et al. Arthritis Research & Therapy* (2017) 19:136

Page 2 of 11

Background

Granulomatosis with polyangiitis (GPA) is a severe systemic autoimmune disease of unknown etiology. The hallmark of the disease is the presence of antineutrophil cytoplasmic autoantibodies (ANCAs) mainly directed against protienase-3 (PR3) [1]. GPA is characterized by necrotizing granulomatosis in the respiratory tract, and a systemic vasculitis preferentially affecting pulmonary and renal small- and medium-sized blood vessels. The abundance of T cells in these vasculitic and granulomatous lesions of GPA patients support their involvement in disease pathogenesis [2]. There is substantial evidence of activated T cells and antigen-driven T cell responses in GPA [3–5] In addition, remission has been induced with therapeutics directed against T cells in patients with refractory GPA [6, 7]. These studies strongly indicate a T cell-mediated pathology in this disease.

The involvement of cluster of differentiation (CD)4$^+$ T helper (T$_H$) cells in the pathogenesis of GPA has been suggested to depend on disease activity, and whether the disease is localized, i.e. restricted to the respiratory tract, or generalized. Prior to the discovery of T$_H$17 cells, research in GPA focused on the disturbed balance between T$_H$1 and T$_H$2 cells. It was found that GPA patients with active disease demonstrated a dysregulated cytokine prolife of circulating T cells with increased IFN-γ production versus a normal interleukin (IL)-4 production [8]. Additional studies demonstrated the presence of T$_H$1-associated markers in the circulation as well as in nasal granulomatous lesions of patients with localized disease, while T$_H$2-associated markers were dominant in generalized disease [9–11]. More recently, levels of IL-17A, the T$_H$17-associated cytokine, were found to be elevated in serum of GPA patients irrespective of active or quiescent disease [12]. In addition, a relative increase in autoantigen-specific T$_H$17 cells in GPA patients has been reported [12, 13].

Defects in regulatory T cell (T$_{REG}$) function in GPA patients may contribute to abnormal skewing in T$_H$ cell responses and may result in an expansion of the CD4$^+$ effector memory T (CD4$^+$ T$_{EM}$) cell population [14]. In addition, altered T$_H$ cell distribution in GPA patients may be in part driven by chronic cytomegalovirus (CMV) infection [15]. We have demonstrated previously that circulating CD4$^+$ T$_{EM}$ cells (CCR7$^-$CD45RO$^+$) in GPA patients were proportionally increased during remission [16], but were decreased during renal active disease upon migration to the inflammatory site [17]. However, during active renal disease not all circulating CD4$^+$ T$_{EM}$ cells tend to migrate to the target tissues [17]. It is possible that a subset of circulating CD4$^+$ T$_{EM}$ cells have a distinct migratory capacity and pathogenic function in GPA patients related to distinct clinical manifestations.

The recruitment of the CD4$^+$ T$_{EM}$ cells to inflammatory sites is orchestrated by their chemokine receptors. Analysis of chemokine receptor expression has been instrumental in the characterization of memory T$_H$ subsets with distinct cytokine patterns and antigen responses [18]. The expression pattern of four chemokine receptors allows the identification of CD4$^+$ T$_{EM}$ subsets, which are defined as T$_{EM}$1 [C-C chemokine receptor (CCR)6$^-$ CXC chemokine receptor 3 (CXCR3)$^+$CCR4$^+$CRTh2$^-$] T$_{EM}$2 (CCR6$^-$CXCR3$^-$CCR4$^+$CRTh2$^+$), T$_{EM}$17 (CCR6$^+$CXCR3$^-$CCR4$^+$CRTh2$^-$) [19, 20], and a subset that exhibits both T$_H$17 and T$_H$1 features, referred to as T$_{EM}$17.1 (CCR6$^+$CXCR3$^+$CCR4$^-$ CRTh2$^-$) [21, 22].

The aim of the present study was to determine the distribution of circulating CD4$^+$ T$_{EM}$ cell subsets based on chemokine receptor expression in GPA patients. Identification of particular circulating CD4$^+$ T$_{EM}$ subsets may reveal distinct associations of specific CD4$^+$ T$_{EM}$ subsets with clinical manifestations or with autoantibodies in GPA patients.

Methods

Study population

Peripheral blood was collected from 63 GPA patients in remission (r-GPA) and 42 age- and sex-matched healthy controls (HCs) in a cross-sectional study..The r-GPA patients fulfilled the criteria of the American College of Rheumatology and the Chapel Hill Consensus Conference definition for GPA [23, 24]. Only patients with PR3-ANCA positivity at diagnosis, and complete remission of their disease at the time of sampling, were included in the study. The PR3-ANCA titers were measured by indirect immunofluorescence (IIF) on ethanol-fixed human granulocytes according to the standard procedure as described previously [25]. ANCA titers lower than 1:20 were considered negative. Complete remission was defined as the complete absence of clinical signs and symptoms of active vasculitis, as indicated by a score of zero on the Birmingham Vasculitis Activity Score (BVAS) [26]. According to these criteria, blood samples were taken during a visit to our outpatient clinic.

Disease extent was defined as localized when GPA was restricted to the upper and lower respiratory tract and generalized when systemic disease with vasculitis extended to more clinical manifestations including involvement of kidneys, joints, eye, and nervous system. None of the patients and controls experienced an infection at the time of sampling.

Twenty-nine of 63 r-GPA patients were treated with maintenance immunosuppressive therapy at time of blood sampling. Three r-GPA patients received azathioprine, 12 r-GPA patients received azathioprine in combination with prednisolone, six r-GPA patients were

Lintermans *et al. Arthritis Research & Therapy* (2017) 19:136

Page 3 of 11

treated with low-dose prednisolone, seven r-GPA patients received low-dose prednisolone in combination with mycophenolate mofetil (MMF), and one r-GPA patient was treated with methotrexate.

Detailed clinical and laboratory characteristics of the patients are summarized in Table 1. All patients and healthy volunteers provided informed consent and the local medical ethics committee approved the study.

Sample preparation and immunophenotyping by flow cytometry

EDTA-anticoagulated peripheral blood was obtained by venipuncture from r-GPA patients and HCs. Whole blood samples were stained within 4 hours after blood withdrawal with appropriate concentrations of fluorochrome-conjugated monoclonal antibodies for cell surface antigens. The samples were immediately processed to obtain the most sensitive detection for the chemokine receptor expression and to minimize cell manipulation. The peripheral blood was stained using the following monoclonal antibodies for cell surface antigens in combination: Alexa Fluor® 700-conjugated anti-CD3, eFluor® 450 (eF450)-conjugated anti-CD4 (both from eBioscience, San Diego, CA, USA), fluorescein isothiocyanate (FITC)-conjugated anti-CD45RO, phycoerythrin-cyanin7 (PE-C7)-conjugated anti-CCR7 (both from BD Biosciences, Franklin Lakes, NJ, USA), PE-conjugated anti-CRTh2, allophycocyanin-C7 (APC-Cy7)-conjugated anti-CXCR3, peridin chlorophyll α-protein (PerCP-Cy5.5-conjugated anti-CCR4, and Brilliant Violet 605™ (BV605)-conjugated anti-CCR6 (all from BioLegend, San Diego, CA, USA). The appropriated isotype-matched control antibodies of irrelevant specificity were added to a separate tube as negative controls. Samples were incubated for 15 minutes at room temperature. Afterward, cells were treated with 2 mL diluted FACS lysing solution (BD Biosciences) for 10 minutes. Finally, the samples were washed in PBS containing 1% (w/v) bovine serum albumin (BSA), and immediately analyzed by eight-color flow cytometric analyses on BD™ LSR II flow cytometer. Data were collected for $1.0 * 10^6$ events for each sample and plotted using Kaluza v1.2 (Beckman Coulter, Brea, CA, USA). Lymphocytes were gated for analysis based on forward and side scatter properties. Positively and negatively stained populations were calculated by quadrant dot-plot analysis or histograms, determined by the appropriate isotype controls. Within the $CD4^+$ T_{EM} cell subset ($CD4^+CCR7^-CD45RO^+$) the expression pattern of chemokine receptors $CCR6^-CXCR3^+CCR4^-CRTh2^-$, $CCR6^-CXCR3^-CCR4^+CRTh2^+$, $CCR6^+CXCR3^-CCR4^+CRTh2^-$, and $CCR6^+CXCR3^+CCR4^-CRTh2^-$ were used to distinguish $T_{EM}1$, $T_{EM}2$, $T_{EM}17$, and $T_{EM}17.1$ cells, respectively.

Table 1 Laboratory and clinical characteristics of r-GPA patients and HC

	r-GPA	HC
Subjects, n (% male)	63 (% 44)	42 (% 40)
Age, mean (range)	62.3 (26.8–85.2)	57.2 (21.5–86.8)
PR3-ANCA[a], n (% positive)	39 (% 62)	
PR3-ANCA titer, median (range)	1:40 (0–1:640)	
Creatinine umol/L, median (range)	86 (52–224)	
CRP mg/L, median (range)	2.7 (0.3–99)	
eGFR ml/min*1.73 m^2, median (range)	64 (21–109)	
CMV seropositive, n (% positive) (N.D.)	33 (% 54) (2)	21 (% 58) (6)
S. aureus, n (% positive) (N.D.)	27 (% 44) (1)	
BVAS, mean	0	
Disease duration in years, median (range)	9.6 (1.9–42.7)	
No. of total relapses, median (range)	1 (0–7)	
Relapser[b], n (%)	43 (% 68)	
Disease type, n (% generalized)	52 (% 83)	
Treatment at time of sampling, n (%)		
Azathioprine	3 (% 5)	
Azathioprine + prednisolone	12 (% 19)	
Prednisolone	6 (% 10)	
Mycophenolate mofetil + prednisolone	7 (% 11)	
Methotrexate	1 (% 2)	
No immunosupressive treatment	34 (% 54)	
Co-trimoxazole, high dose/low dose/no dose	17/15/31	
No. of organs involved, median (range)	3 (1–7)	
Clinical manifestations, n (%)		
Renal	35 (% 56)	
ENT	45 (% 71)	
Joints	36 (% 57)	
Pulmonary	40 (% 63)	
Nervous system	20 (% 32)	
Eyes	24 (% 38)	
Cutaneous	13 (% 21)	
Other	7 (% 11)	

Characteristics at sampling time point
BVAS Birmingham Vasculitis Activity Score, *CMV* cytomegalovirus, *CRP* C-reactive protein, *eGFR* estimated glomerular filtration rate, *ENT* ear, nose and throat, *GPA* granulomatosis with polyangiitis, *HC* healthy control, *PR3-ANCA* antineutrophil cytoplasmic antibodies targeting proteinase 3, *r-GPA* GPA patient in remission, *S. aureus* Staphylococcus aureus
[a]ANCA-positive titer ≥1:40, ANCA-negative ≤1:20
[b]Relapser: GPA patient that had ≥1 relapse after diagnosis until time of sampling

Detection of S. aureus

From 62 r-GPA patients, *S. aureus* nasal carriers were determined as described previously [27]. Briefly, *S. aureus*

Lintermans *et al. Arthritis Research & Therapy* (2017) 19:136

Page 4 of 11

nasal isolates were sampled by rotating a sterile cotton swab in each anterior nary. Swabs were inoculated on 5% sheep-blood and salt mannitol agar for 72 h at 35 °C. *S. aureus* was identified by coagulase and DNase positivity. Patients were considered to be chronic nasal carriers when ≥50% of their nasal cultures grew *S. aureus.*

CMV ELISA

CMV-specific IgG was determined in serum samples using an in-house enzyme-linked immunosorbent assay (ELISA). In brief, 96-well ELISA plates (Greiner, Kremsmünster, Austria) were coated overnight with lysates of CMV-infected fibroblasts. Lysates of non-infected fibroblasts were used as negative controls. Following coating, serial (1:100–1:3200) dilutions of serum samples were incubated for 45 minutes. Next, goat anti-human IgG-HRP (Southern Biotech, Birmingham, AL, USA) was added and incubated for 45 minutes. Samples were incubated with TBE substrate (Sigma-Aldrich, St. Louis, MO, USA) for 15 minutes and the reaction was stopped with sulfuric acid. The plates were scanned on a Versamax reader (Molecular Devices, Sunnyvale, CA, USA). A pool of sera from three CMV-seropositive individuals with known concentrations of CMV-specific IgG was used to quantify levels of CMV-specific IgG in the tested samples.

Statistical analysis

Statistical analysis was performed using SPSS v22 (IBM Corporation, Armonk, NY, USA) and GraphPad prism v5.0 (GraphPad Software, San Diego, CA, USA). Data are presented as median values. Data were analyzed with the D'Agostino-Pearson omnibus normality test for Gaussian distribution. For comparison between r-GPA patients and HCs the unpaired *t* test was used for data with Gaussian distribution and the Mann-Whitney *U* test for data without Gaussian distribution. For intra-individual comparison of values at multiple time points during follow-up, repeated measures analysis of variance was used if data were normally distributed and a Friedman test was used if data had a non-Gaussian distribution. The association between clinical parameters and CD4$^+$ T_{EM} cell subsets in inclusion samples of r-GPA patients was investigated using the Spearman's rank correlation coefficient. In order to account for interactions of CMV and age on the percentage of CD4$^+$T cells subsets and CD4$^+$$T_{EM}$ cell subsets we used a linear (Enter) regression analysis. Non-normally distributed data were log-transformed. Differences were considered statistically significant at two-sided *p* values equal to or less than 0.05.

Results

Higher frequency of CD4$^+$ T_{EM} cells in peripheral blood of GPA patients in remission

We have previously reported that r-GPA patients have an increased percentage of circulating CD4$^+$ T_{EM} cells

compared to HC [16]. Here, we confirm that within the CD4$^+$ T cell population in the peripheral blood of r-GPA patients the frequency of CD4$^+$ T_{EM} cells was significantly higher compared to HCs (Fig. 1b). In addition, the frequency of CD4$^+$ $T_{Naïve}$ cells was significantly lower in r-GPA patients compared to HCs, whereas the proportions of CD4$^+$ T_{CM} cells did not differ between r-GPA patients and HCs. The proportions of CD4$^+$ T_{TD} cells were higher in r-GPA compared to HCs.

Increased frequency of CD4$^+$$T_{EM}$17 and decreased frequency of CD4$^+$$T_{EM}$1 in peripheral blood of patients with GPA

Having demonstrated a significant increase in the frequency of CD4$^+$ T_{EM} cells in r-GPA patients we next zoomed in on the phenotypic distribution within this expanded population. As mentioned earlier, CD4$^+$ T_{EM} cell population can be subdivided into four T_{EM} subsets based on their differential expression of the chemokine receptors CCR6, CCR4, CXCR3 and CRTh2. We applied a chemokine receptor gating strategy, as shown in Fig. 1a, to identify the distribution of circulating T_{EM}1 (CCR6$^-$CXCR3$^+$CCR4$^-$CRTh2$^-$), T_{EM}2 (CCR6$^-$CXCR3$^-$CCR4$^+$CRTh2$^+$), T_{EM}17 (CCR6$^+$CXCR3$^-$CCR4$^+$CRTh2$^-$), and T_{EM}17.1 (CCR6$^+$CXCR3$^+$CCR4$^-$CRTh2$^-$) cell subsets among the CD4$^+$ T_{EM} cells. The analysis demonstrated a significant decrease in the frequency of T_{EM}1 and T_{EM}17.1 cells in r-GPA patients compared to HCs (Fig. 1c). The frequencies of T_{EM}17 cells were significant higher in r-GPA compared to HCs. No statistical significant difference was reached for the distribution of T_{EM}2 cells between r-GPA patients and HCs. In addition, no changes were observed in the percentages of both T_{EM}1, and T_{EM}17 subsets in three consecutive samples during 6 months of follow-up in individual r-GPA patients (data not shown). Furthermore, we observed CXCR3$^+$CCR4$^+$ (double positive, DP) and CXCR3$^-$CCR4$^-$ (double negative, DN) CCR6$^+$ T_{EM} cells. Although little is known about the function of these cells, it has been described that the DP CCR6$^+$ T_{EM} cells produce low levels of IL-17A and RORC with intermediate IFN-γ and T-bet levels [28]. In our study, we did not observe differences in these unclassified DP and DN population of either CCR6$^+$ or CCR6$^-$ CD4$^+$$T_{EM}$ cells between r-GPA patients and HCs (data not shown).

The frequency of T_{EM}17 cells negatively correlates with the frequency of T_{EM}1 cells in peripheral blood of r-GPA patients

In vitro and in vivo studies have provided evidence that T_H1 and T_H17 cell responses counterregulate each other during disease development in GPA [13, 29]. Therefore, we investigated whether the increased proportion of T_{EM}17 cells correlated with the decreased proportion of T_{EM}1

Lintermans *et al. Arthritis Research & Therapy* (2017) 19:136

Page 5 of 11

Fig. 1 T cell subset distribution between HC and r-GPA patients. **a** Gating strategy of CD4$^+$ T$_{EM}$ cell subsets using chemokine receptor expression patterns. The flow cytometry plots show sequential gating (*dashed arrows*) to identify different CD4$^+$ T$_{EM}$ cell subsets within the CD4$^+$T$_{EM}$ cell population. CD4$^+$ T cell subsets from peripheral blood were identified based on the expression of CCR7 and CD45RO. Within CD4$^+$T$_{EM}$ cells CCR6$^-$ and CCR6$^+$ cells were identified based on the isotype (*grey histogram with dashed line*). Within CCR6$^-$ CD4$^+$T$_{EM}$ cells expression of CXCR3 and CCR4 was analyzed to identify T$_{EM}$1 cells (CD4$^+$CD45RO$^+$CCR7$^-$CCR6$^-$CXCR3$^+$CCR4$^-$). Expression of CRTh2 was used to identify lineage-committed T$_{EM}$2 cells (CD4$^+$CD45RO$^+$CCR7$^-$CCR6$^-$CXCR3$^-$CCR4$^+$CRTh2$^+$) derived from CCR6$^-$CXCR3$^-$CCR4$^+$ CD4$^+$T$_{EM}$ cells. The CXCR3 and CCR4 expression was also analyzed on CCR6$^+$ CD4$^+$T$_{EM}$ cells to identify T$_{EM}$17 cells (CD4$^+$CD45RO$^+$CCR7$^-$CCR6$^+$CXCR3$^-$CCR4$^+$), and T$_{EM}$17.1 cells (CD4$^+$CD45RO$^+$CCR7$^-$CCR6$^+$CXCR3$^+$CCR4$^-$). The unclassified populations within the CCR6$^-$ and CCR6$^+$ populations were identified, that were double-negative (*DN*) or double-positive (*DP*) for CXCR3 and CCR4. Representative flow cytometry plots from one r-GPA patient. **b** Percentages of CD45RO$^-$CCR7$^+$ (*T$_{NAIVE}$*), CD45RO$^+$CCR7$^+$ (*T$_{CM}$*), CD45RO$^+$CCR7$^-$ (*T$_{EM}$*) and CD45RO$^-$CCR7$^-$ (*T$_{TD}$*) subpopulations within the CD4$^+$ T cell population in peripheral blood of HCs (*open circles; n = 42*) and r-GPA patients (*filled squares; n = 63*). **c** The percentage of CD4$^+$ T$_{EM}$ cell subsets in peripheral blood of HCs (*open circles; n = 42*) and r-GPA patients (*filled squares; n = 63*). *Black squares* indicate r-GPA patients on treatment (*n = 29*), *grey squares* indicate r-GPA patients off treatment (*n = 34*). *Horizontal lines* represent median percentages. $^*p < 0.05$, $^{**}p < 0.01$, and $^{***}p < 0.001$. *CCR* C-C chemokine receptor, *CD* cluster of differentiation, *CXCR3* CXC chemokine receptor 3, *HC* healthy control, *r-GPA* GPA patient in remission, *T$_{EM}$* effector memory T cell

cells. As shown in Fig. 2, a significant negative correlation between decreased proportions of T$_{EM}$1 cells and increased proportions of T$_{EM}$17 cells was observed in r-GPA patients (Spearman's rho = -0.844, $p < 0.0001$). However, neither T$_{EM}$2 cells nor T$_{EM}$17.1 cells correlated significantly with T$_{EM}$17 cells (Fig. 2a). Similar observations were found for HCs, although the correlation between T$_{EM}$1 and T$_{EM}$17 cells (Spearman's rho = −0.554) was less

pronounced in comparison to r-GPA patients (Spearman's rho = −0.844) (Fig. 2b).

Immunosuppressive therapy and the imbalance in CD4$^+$ T$_{EM}$ cell subsets

To address the question whether current immunosuppressive treatment influences the imbalance in T$_{EM}$1 and T$_{EM}$17 cell subsets, r-GPA patients were separated

Lintermans et al. Arthritis Research & Therapy (2017) 19:136

Page 6 of 11

Fig. 2 $T_{EM}17$ cells negatively correlate with $T_{EM}1$ cells. Correlation between the percentage of $T_{EM}17$ cells and $T_{EM}1$ (*left*), $T_{EM}2$ (*middle*) and $T_{EM}17.1$ (*right*) cells within the CD4$^+$T$_{EM}$ cell population of **a** r-GPA patients (*filled squares*; n = 63), *black squares* patients on treatment (n = 29) and *grey squares* patients off treatment (n = 34) and **b** HC (*open circles*; n = 42). Correlations were determined by Spearman's correlation coefficient (rho) and the level of significance is indicated by the *p* value. *CD* cluster of differentiation, *HC* healthy control, *r-GPA* GPA patient in remission, T_{EM} effector memory T cell

into patients not receiving immunosuppressive treatment (off treatment; n = 34), and patients that did receive immunosuppressive treatment (on treatment; *n* = 29) (Fig. 1c). No significant differences were observed in the frequencies of $T_{EM}1$ cells between the untreated and treated r-GPA patients (median 12.3%, interquartile rang 9.5–17.8% vs 9.0%, 5.6–19.2%). In addition, no significant differences were detected in the frequencies of $T_{EM}17$ cells between untreated and treated r-GPA patients (22.3%, 18.0–26.5% vs 26.5%, 17.2–35.4%). Therefore, immunosuppressive treatment at time of sampling was not responsible for the imbalances observed between the $T_{EM}1$ and $T_{EM}17$ cell subsets.

The influence of *S. aureus* and CMV infection on the frequencies of circulating $T_{EM}1$ and $T_{EM}17$ cells in GPA patients

Physiologically, T_H17 cells are important in the defense against bacterial infection (e.g. *Staphylococcus aureus* (*S. aureus*)), by IL-17-mediated activation of neutrophils. Interestingly, chronic nasal carriage of *S. aureus* has been suggested to drive the T_H17 response in ANCA-associated vasculitis (AAV) [30]. Therefore we investigated whether chronic nasal carriage of *S. aureus* influenced the proportions of $T_{EM}1$ and $T_{EM}17$ cells. No significant differences were found in the proportion of $T_{EM}1$ and $T_{EM}17$ cells between r-GPA patients with or without *S. aureus* nasal carriage (Fig. 3a), even after excluding co-trimoxazole treatment (data not shown).

Besides bacterial infections, latent viral infection can also influence the T cell compartment in humans. The expansion in CD4$^+$ T$_{EM}$ cells in GPA patients has been

suggested to be driven by latent cytomegalovirus (CMV) [15]. Here, we found a slight increase in the percentage of circulating CD4$^+$T$_{EM}$ cells of CMV-seropositive compared to CMV-seronegative populations. This difference was statistically significant in r-GPA patients (*p* = 0.044), but not in HCs (*p* = 0.234) (Fig. 3b). In addition, both CMV-seropositive and CMV-seronegative r-GPA patients showed significantly increased percentages of CD4$^+$T$_{EM}$ cells compared to CMV-seropositive HCs.

To investigate the possibility that the shift from T_H1 toward T_H17 cells in GPA patients was the result of CMV carriage, we compared the proportions of $T_{EM}1$ and $T_{EM}17$ cells between CMV-seropositive and CMV-seronegative r-GPA patients. As shown in Fig. 3c, CMV-seropositive r-GPA patients demonstrated significantly higher frequencies of $T_{EM}1$ cells and significantly lower frequencies of $T_{EM}17$ cells compared to CMV-seronegative r-GPA patients. In contrast, CMV serostatus in HCs did not change the proportions of $T_{EM}1$ cells but a small decrease in the percentage of $T_{EM}17$ cells in CMV-seropositive HCs compared to CMV-seronegative HCs was observed.

Furthermore, CMV-specific serum IgG levels in r-GPA patients showed a positive correlation with the percentage of $T_{EM}1$ cells (Spearman's rho = 0.408, *p* < 0.001) and a negative correlation with the percentage of $T_{EM}17$ cells (Spearman's rho = −0.468, *p* < 0.0001).

Association of $T_{EM}1$ and $T_{EM}17$ frequencies with laboratory and clinical parameters

We next explored whether disturbed frequencies in $T_{EM}1$ and $T_{EM}17$ cells correlated with various laboratory

Lintermans *et al. Arthritis Research & Therapy* (2017) 19:136

Page 7 of 11

Fig. 3 $T_{EM}1$ and $T_{EM}17$ cell distribution between r-GPA patients with *S. aureus* nasal carriage and latent CMV infection. **a** The circulating percentage of $T_{EM}1$ and $T_{EM}17$ cells within the CD4$^+$$T_{EM}$ cell population in peripheral blood of *S. aureus*-non-carrying r-GPA patients (*open squares*; n = 35) and carrying r-GPA patients (*filled squares*; n = 27). **b** The circulating percentage of CD4$^+$$T_{EM}$ cells within the CD4$^+$ T cell population in peripheral blood, and **c** the circulating percentage of $T_{EM}1$ and $T_{EM}17$ cells within the CD4$^+$$T_{EM}$ cell population in peripheral blood of HC CMV-seronegative (*open circles*; n = 15), CMV-seropositive (*filled circles*; n = 21), r-GPA patients CMV-seronegative (*open squares*; n = 28), and CMV-seropositive (*filled squares*; n = 33). *Horizontal lines* represent median percentages. $^*p < 0.05$, $^{**}p < 0.01$, and $^{***}p < 0.001$. *CD* cluster of differentiation, *CMV* cytomegalovirus, *HC* healthy control, *ns* not significant, *r-GPA* GPA patient in remission, *S. aureus*, *Staphylococcus aureus*, T_{EM} effector memory T cell

and clinical parameters of r-GPA patients (Table 2). Serum ANCA titers in GPA patients have often been related to disease activity and risk of relapse. Therefore, we investigated the relation between ANCA titer at time of sampling and the proportions of $T_{EM}1$ and $T_{EM}17$ cells in r-GPA patients. No correlation was observed between ANCA titers and the frequencies of either $T_{EM}1$ cells or $T_{EM}17$ cells. In addition, no correlations were found between frequencies of either $T_{EM}1$ cells or $T_{EM}17$ cells and any other laboratory parameter measured at the time of inclusion, including creatinine levels, C-reactive protein (CRP) serum levels, and epidermal growth factor receptor (eGFR).

Interestingly, the accumulating number of organs involved over the total disease course correlated negatively with the frequency of $T_{EM}1$ cells (Spearman's rho = -0.264, $p = 0.037$) but correlated positively with $T_{EM}17$ cells (Spearman's rho = 0.390, $p = 0.002$). In addition, generalized r-GPA patients showed lower frequencies of $T_{EM}1$ cells in comparison to localized r-GPA patients (10.7%, 6.3–16.5% vs 17.9%, 12.6–20.4%, $p = 0.016$). The

frequencies of $T_{EM}17$ cells were higher in generalized r-GPA compared to localized r-GPA patients (24.8%, 19.2–30.8% vs 19.3%, 15.0–21.4%, $p = 0.037$). This indicates that r-GPA patients with more systemic manifestations have an increased $T_{EM}17$-mediated immune response, whereas r-GPA patients with more local manifestations have a more $T_{EM}1$-directed immune response. However, disease duration and total number of relapses did not correlate with either the frequencies of $T_{EM}1$ cells or $T_{EM}17$ cells. Of note, we observed that r-GPA patients that did encounter one or more relapses after diagnosis (1 ≥ relapse r-GPA, $n = 43$) had higher frequencies of circulating $T_{EM}17$ cells and lower frequencies of circulating $T_{EM}1$ cells in comparison to r-GPA that experienced no relapse (non-relapse r-GPA, $n = 20$) since diagnosis (Fig. 4).

### Interaction of CMV serostatus and age on the different T cell subsets

The results described above regarding the differences between r-GPA patients and HCs in percentage of CD4$^+$$T_{EM}$

Table 2 Associations of $T_{EM}1$ cell and $T_{EM}17$ cell percentages with clinical parameters

Clinical parameters	% $T_{EM}1$ cells		% $T_{EM}17$ cells	
	Spearman's rho	*p* value	Spearman's rho	*p* value
PR3-ANCA titer	0.026	0.839	−0.048	0.707
Creatinine (umol/L)	−0.039	0.759	0.164	0.198
CRP (mg/L)	0.047	0.715	0.015	0.909
eGFR (mL/min*1.73 m^2)	−0.079	0.540	−0.006	0.962
Disease duration (years)	−0.023	0.857	0.063	0.626
No. of total relapses	−0.148	0.246	0.181	0.155
No. of organs involved	−0.264*	0.037	0.390**	0.002

CRP C-reactive protein, *eGFR* estimated glomerular filtration rate, *PR3-ANCA* antineutrophil cytoplasmic antibodies targeting proteinase 3, *TEM* effector memory T cell
* $p < 0.05$ and ** $p < 0.01$

Lintermans *et al. Arthritis Research & Therapy* (2017) 19:136

Page 8 of 11

Fig. 4 $T_{EM}1$ and $T_{EM}17$ cell distribution between relapsing and non-relapsing r-GPA patients. The circulating frequencies of $T_{EM}1$ and $T_{EM}17$ cells within the CD4$^+$$T_{EM}$ cell population in peripheral blood of non-relapsing r-GPA patients (*open squares*; $n = 20$) and r-GPA patients that experienced ≥ 1 relapse during their disease course until inclusion in this study (*filled squares*; $n = 43$). *Horizontal lines* represent median percentages. $^*p < 0.05$. *CD* cluster of differentiation, *r-GPA* GPA patient in remission, T_{EM} effector memory T cell

cells, $T_{EM}1$ and $T_{EM}17$ cells may indicate a possible interaction between CMV and age, as both factors influence the T cell memory compartment. To analyze this interaction a linear regression was performed that included interaction of CMV and age. This analysis demonstrated that differences in CD4$^+$$T_{EM}$ cells, $T_{EM}1$ cells, and $T_{EM}17$ cells between r-GPA patients and HCs were not attributed to CMV serostatus and age (see Additional file 1). Moreover, differences in $T_{EM}1$ between relapse r-GPA patients and non-relapse r-GPA patients were not affected by CMV serostatus and age. The difference in $T_{EM}17$ cells between relapse r-GPA patients and non-relapse r-GPA patients was minimally influenced by CMV serostatus and age as the differences for both factors were borderline significant.

Thus, CMV and age did not influence the differences in expansion of CD4$^+$$T_{EM}$ cells, $T_{EM}1$ cells, and $T_{EM}17$ cells, in both r-GPA patients and HCs.

Discussion

In this study, we aimed to determine the distribution of circulating CD4$^+$ T_{EM} cell subsets based on chemokine receptor expression in GPA patients. We demonstrated a significant increase in the proportion of $T_{EM}17$ cells with a concomitant decrease in the proportion of $T_{EM}1$ cells in peripheral blood of patients with r-GPA. Increased proportions of $T_{EM}17$ cells were more pronounced in r-GPA patients with systemic manifestations, whereas r-GPA patients with local manifestations showed a remarkable increase in $T_{EM}1$ cells. Interestingly, CMV seropositivity appeared to modulate the disturbed balance of $T_{EM}1$ and $T_{EM}17$ cells in r-GPA patients.

The decreased proportions of $T_{EM}1$ cells in r-GPA patients compared to HCs reflect an aberrant $T_{EM}1$ response in patients. It has been demonstrated that GPA patients with active or localized disease show a polarization toward a T_H1-type response [8, 11, 31]. These studies showed an abundant T_H1 cytokine (IFN-γ) and chemokine

(CCR5) pattern on circulating T cells, as well as in granulomatous lesions compared to patients in remission or with generalized disease [11, 31]. It has been suggested that the disturbed T_H1 response might play a role in the initiation of GPA. The disease can progress into a generalized GPA with a less prominent T_H1-type response. The majority of r-GPA patients included in this study present generalized disease with a median disease duration of 9.6 years. This might explain the decreased proportion of circulating $T_{EM}1$ cells in our r-GPA patients. However, one may also argue that the relative decrease in circulating $T_{EM}1$ cells is due to an increased tissue migration of these cells. In GPA patients with generalized disease it has been reported that renal lesions show polarization toward T_H1 type-responses [32]. However, we did not observe an association of $T_{EM}1$ cells with renal involvement in r-GPA patients.

Our results regarding the increase in $T_{EM}17$ response in GPA patients are in line with previous reports on increased T_H17-associated activity in these patients. It has been reported that antigen-specific T_H17 cells are expanded in GPA patients, irrespective of disease activity and maintenance therapy [13, 33]. In addition, serum IL-17A levels are also found to be elevated in active GPA patients and remained elevated in GPA patients recovering from active disease [12]. In line with this result, we observed a sustained $T_{EM}17$ expansion over a period of 6 months in our r-GPA patients. Altogether, the involvement of T_H17 cells in the immunopathology in GPA appears to be well established, although presently it remains unclear which mechanisms initiate T_H17 responses in GPA. Possible explanations for the expanded $T_{EM}17$ population might be related to the presence of granulomas, or chronic nasal carriage of *S. aureus* in GPA.

Granulomas are sophisticated and highly organized structures that typically consist of a sphere of highly activated macrophages surround by T lymphocytes. They provide a specialized niche for macrophage-T cell

Lintermans *et al. Arthritis Research & Therapy* (2017) 19:136

Page 9 of 11

interaction, contributing to the differentiation and maturation of T cells [34]. The pro-inflammatory cytokine environment in granuloma may contribute to the aberrant T_H1 and T_H17 cell distribution found in the circulation. Since, granulomas are common clinical manifestations in GPA patients they may provide an ideal environment for $T_{EM}17$ cell expansion. Engagement of $CD4^+T_{EM}$ cells with IL-6/TGFβ-producing macrophages may promote $CD4^+T_{EM}$ cell differentiation into $T_{EM}17$ cells. In addition, macrophages also secrete IL-23, which sustains the T_H17 population. Indeed, elevated serum levels of TGFβ, IL-6, and IL-23 have been reported in GPA, and, importantly, elevated levels of IL-23 correlated with disease severity in patients with GPA [12].

Chronic carriage of *S. aureus* constitutes a risk factor for the development of exacerbations in GPA. We have previously shown that the frequency of chronic nasal carriage of *S. aureus* is higher in GPA patients compared to HC [30]. Moreover, it was shown that nasal *S. aureus* carriage is associated with increased risk of relapse [30, 35]. Staphylococcal superantigens act as potent immune stimulators for T cells, resulting in polyclonal T cell proliferation and pro-inflammatory cytokine production [36]. In vitro studies demonstrated that stimulating T cells with staphyloccal exotoxins (alpha-toxin and SEB), strongly induced IL-17A-secreting T cells [13, 37]. Therefore, the involvement of T_H17 cells in GPA may possibly be driven by chronic nasal carriage of *S. aureus.* However, we did not observe increased frequencies of $T_{EM}17$ cells in GPA patients carrying *S. aureus*. This observation is in line with earlier studies in GPA patients in which no correlation between the presence of staphylococcal superantigens and the expansion of T cell subsets in peripheral blood was found [27].

Remarkably, we observed that the proportion of $T_{EM}17$ cells in r-GPA patients was highly associated with CMV serostatus with frequencies of $T_{EM}17$ cells being decreased in CMV-seropositive r-GPA patients as compared to seronegative r-GPA patients. These observations indicate that latent infection with human CMV modulates the distribution of T_{EM} cell subsets, although the underlying mechanisms are unclear. For instance, CMV seropositivity is strongly associated with the presence of memory T cells. It has been demonstrated that only CMV-seropositive individuals possess significant numbers of $CD4^+CD28^-$ T cells and many of these T cells respond to CMV [38]. In fact, the expansion of $CD4^+CD28^-$ T cells in GPA is suggested to be driven by CMV infections, and is associated with increased risk of infection and mortality [15]. However, the precise role of CMV infection in T_H1 and T_H17 responses is poorly understood. Previous studies indicate that T cells expressing CXCR3 (T_H1 type) arise during primary CMV infection and are maintained during latency [39]. In line

with this study, we observed increased proportions of $T_{EM}1$ cells in the circulation of CMV-seropositive r-GPA patients. The skewing toward a $T_{EM}1$ response in CMV-seropositive r-GPA patients could also explain the decrease in the proportion of $T_{EM}17$ cells since these two T_{EM} cells subsets inversely correlate with each other. Importantly, the difference in $T_{EM}1$ cells between r-GPA patients and HCs was not influenced by CMV and age. Additionally, CMV serostatus did not influence the proportions of $T_{EM}1$ cells in HCs whereas in r-GPA patients CMV serostatus had a major impact on both the proportions of $T_{EM}1$, and $T_{EM}17$ cells.

T_H17 cells may also induce autoimmune responses. Very recently, it was shown that the frequency of T_H17 cells ($CCR6^+$) in rheumatoid arthritis (RA) patients is associated with anti-citrullinated protein antibodies (ACPA) status [28]. In particular, $CCR6^+$ T_H cell proportions were higher in ACPA-positive RA patients in comparison to ACPA-negative RA patients, and inversely correlated with disease duration in ACPA-negative patients. If this were the case in GPA patients, one may argue that the increase in $T_{EM}17$ cells might be associated with ANCA status and could be a tool to discriminate ANCA-positive patients from those that are ANCA-negative. In contrast to the data in RA patients, we did not observe any association regarding ANCA status with the frequency of $T_{EM}17$ cells in r-GPA patients. This is possibly due to the fact that ANCA titers in GPA patients fluctuate during the disease course, whereas ACPA-positive RA patients consistently remain ACPA-positive over time. On the other hand, we found that $T_{EM}17$ cells in GPA patients showed a positive association with organ involvement, whereas $T_{EM}1$ cells were negatively associated with organ involvement. This suggests a more severe disease course in individuals with a high frequency of $T_{EM}17$ cells. Furthermore, we observed that persistent $T_{EM}17$ expansion is associated with a higher tendency to relapse.

The current study was designed as a cross-sectional study using peripheral blood of quiescent GPA patients and HCs. The main limitations are the lack of absolute lymphocyte counts and study samples from GPA patients with active disease. Therefore, the current data only provides observational information of proportions of circulating $CD4^+$ T_{EM} cell subsets in r-GPA patients. Further studies are warranted to assess blood samples from patients during active disease and to study the distribution of infiltrated T_{EM} cell subsets in nasal and renal biopsies to elucidate distinct migratory capacities of $T_{EM}1$ and $T_{EM}17$ cells and to confirm their role in inflamed target tissues in GPA. Since T_{EM} cells also appear in the urine during active renal GPA disease, analysis of urine samples might aid in demonstrating which distinct T_{EM} subsets are possibly involved in renal injury.

Lintermans *et al. Arthritis Research & Therapy* (2017) 19:136

Page 10 of 11

Conclusions

This study describes the distribution of circulating $CD4^+$ T_{EM} cell subsets identified based on chemokine receptor expression in r-GPA patients without any in vitro manipulation. It demonstrates an aberrant balance between $T_{EM}1$ and $T_{EM}17$ cells in r-GPA patients, which is shown to be associated with severity of the disease in terms of organ involvement, and tendency to relapse. Interestingly, the imbalance between $T_{EM}1$ and $T_{EM}17$ cells is modulated in CMV-seropositive r-GPA patients. Accordingly, future T cell phenotype studies should take into account chronic viral infections (i.e. CMV) for $CD4^+T_{EM}$ subset characterization.

Additional file

Additional file 1: Table S1. Linear regression analysis for percentages of CD4 + TEM cells, TEM1, and TEM17 cells between r-GPA patients and HCs. (PDF 208 kb)

Abbreviations

ACPA: Anti-citrullinated protein antibodies; BVAS: Birmingham Vasculitis Activity Score; CCR: C-C chemokine receptor; CD: Cluster of differentiation; CMV: Cytomegalovirus; CRP: C-Reactive protein; CXCR3: CXC chemokine receptor 3; eGFR: Estimated glomerular filtration rate; ELISA: Enzyme-linked immunosorbent assay; ENT: Ear, nose and throat; GPA: Granulomatosis with polyangiitis; HC: Healthy control; IL: Interleukin; PR3-ANCA: Antineutrophil cytoplasmic antibodies targeting proteinase 3; RA: Rheumatoid arthritis; r-GPA: GPA patient in remission; *S. aureus*: Staphylococcus aureus; T_{EM}: Effector memory T cell; T_H: T helper; T_{REG}: regulatory T cell

Availability of data and materials

All data generated or analysed during this study are included in this published article (and its Additional files).

Authors' contributions

LLL performed the experiments, performed statistical analysis, drafted the manuscript, and contributed to concept and design. WHA and PH contributed to concept and design, interpretation of the data, and critically revised the manuscript. AR and CAS contributed to concept and design, inclusion of patients with GPA, analysis and interpretation of clinical data, and critical revision of the manuscript. All authors read and approved the final manuscript.

Authors' information

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Written informed consent was obtained from all study participants. The study was approved by the institutional Medical Ethics Review Board of the University Medical Center Groningen (METc2010/057). All procedures were in accordance with the Declaration of Helsinki.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

[1]Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. [2]Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. [3]Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.

References

1. Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med. 1997;337(21): 1512–23.
2. Gephardt GN, Ahmad M, Tubbs RR. Pulmonary vasculitis (Wegener's granulomatosis). immunohistochemical study of T and B cell markers. Am J Med. 1983;74(4):700–4.
3. Brouwer E, Stegeman CA, Huitema MG, Limburg PC, Kallenberg CG. T cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener's granulomatosis (WG). Clin Exp Immunol. 1994;98(3):448–53.
4. Brouwer E, Tervaert JW, Horst G, et al. Predominance of IgG1 and IgG4 subclasses of anti-neutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener's granulomatosis and clinically related disorders. Clin Exp Immunol. 1991;83(3):379–86.
5. Popa ER, Stegeman CA, Bos NA, Kallenberg CG, Tervaert JW. Differential B- and T-cell activation in Wegener's granulomatosis. J Allergy Clin Immunol. 1999;103(5 Pt 1):885–94.
6. Lockwood CM, Thiru S, Isaacs JD, Hale G, Waldmann H. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet. 1993;341(8861):1620–2.
7. Schmitt WH, Hagen EC, Neumann I, et al. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int. 2004;65(4):1440–8.
8. Ludviksson BR, Sneller MC, Chua KS, et al. Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10. J Immunol. 1998;160(7):3602–9.
9. Schonermarck U, Csernok E, Trabandt A, Hansen H, Gross WL. Circulating cytokines and soluble CD23, CD26 and CD30 in ANCA-associated vasculitides. Clin Exp Rheumatol. 2000;18(4):457–63.
10. Muller A, Trabandt A, Gloeckner-Hofmann K, et al. Localized Wegener's granulomatosis: predominance of CD26 and IFN-gamma expression. J Pathol. 2000;192(1):113–20.
11. Lamprecht P, Bruhl H, Erdmann A, et al. Differences in CCR5 expression on peripheral blood CD4 + CD28- T-cells and in granulomatous lesions between localized and generalized Wegener's granulomatosis. Clin Immunol. 2003;108(1):1–7.
12. Nogueira E, Hamour S, Sawant D, et al. Serum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitis. Nephrol Dial Transplant. 2010;25(7):2209–17.
13. Abdulahad WH, Stegeman CA, Limburg PC, Kallenberg CG. Skewed distribution of Th17 lymphocytes in patients with Wegener's granulomatosis in remission. Arthritis Rheum. 2008;58(7):2196–205.
14. Abdulahad WH, Stegeman CA, Van der Geld YM, Doornbos-van der Meer B, Limburg PC, Kallenberg CG. Functional defect of circulating regulatory CD4+ T cells in patients with Wegener's granulomatosis in remission. Arthritis Rheum. 2007;56(6):2080–91.
15. Morgan MD, Pachnio A, Begum J, et al. CD4 + CD28- T cell expansion in granulomatosis with polyangiitis (Wegener's) is driven by latent cytomegalovirus infection and is associated with an increased risk of infection and mortality. Arthritis Rheum. 2011;63(7):2127–37.

Lintermans *et al. Arthritis Research & Therapy* (2017) 19:136

Page 11 of 11

16. Abdulahad WH, van der Geld YM, Stegeman CA, Kallenberg CG. Persistent expansion of CD4+ effector memory T cells in Wegener's granulomatosis. Kidney Int. 2006;70(5):938–47.

17. Abdulahad WH, Kallenberg CG, Limburg PC, Stegeman CA. Urinary CD4 + effector memory T cells reflect renal disease activity in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2009;60(9): 2830–8.

18. Mahnke YD, Brodie TM, Sallusto F, Roederer M, Lugli E. The who's who of T-cell differentiation: human memory T-cell subsets. Eur J Immunol. 2013; 43(11):2797–809.

19. Bonecchi R, Bianchi G, Bordignon PP, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med. 1998;187(1):129–34.

20. Nagata K, Tanaka K, Ogawa K, et al. Selective expression of a novel surface molecule by human Th2 cells in vivo. J Immunol. 1999;162(3):1278–86.

21. Acosta-Rodriguez EV, Rivino L, Geginat J, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol. 2007;8(6):639–46.

22. Annunziato F, Cosmi L, Santarlasci V, et al. Phenotypic and functional features of human Th17 cells. J Exp Med. 2007;204(8):1849–61.

23. Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum. 1990;33(8):1101–7.

24. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013; 65(1):1–11.

25. Tervaert JW, Mulder L, Stegeman C, et al. Occurrence of autoantibodies to human leucocyte elastase in Wegener's granulomatosis and other inflammatory disorders. Ann Rheum Dis. 1993;52(2):115–20.

26. Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM. 1994;87(11):671–8.

27. Popa ER, Stegeman CA, Bos NA, Kallenberg CG, Tervaert JW. Staphylococcal superantigens and T cell expansions in Wegener's granulomatosis. Clin Exp Immunol. 2003;132(3):496–504.

28. Paulissen SM, van Hamburg JP, Davelaar N, et al. CCR6(+) th cell populations distinguish ACPA positive from ACPA negative rheumatoid arthritis. Arthritis Res Ther. 2015;17:344.

29. Odobasic D, Gan PY, Summers SA, et al. Interleukin-17A promotes early but attenuates established disease in crescentic glomerulonephritis in mice. Am J Pathol. 2011;179(3):1188–98.

30. Stegeman CA, Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CG. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med. 1994; 120(1):12–7.

31. Lamprecht P, Erdmann A, Mueller A, et al. Heterogeneity of CD4 and CD8+ memory T cells in localized and generalized wegener's granulomatosis. Arthritis Res Ther. 2003;5(1):R25–31.

32. Masutani K, Tokumoto M, Nakashima H, et al. Strong polarization toward Th1 immune response in ANCA-associated glomerulonephritis. Clin Nephrol. 2003;59(6):395–405.

33. Wilde B, Thewissen M, Damoiseaux J, et al. Th17 expansion in granulomatosis with polyangiitis (Wegener's): The role of disease activity, immune regulation and therapy. Arthritis Res Ther. 2012;14(5):R227.

34. Hilhorst M, Shirai T, Berry G, Goronzy JJ, Weyand CM. T cell-macrophage interactions and granuloma formation in vasculitis. Front Immunol. 2014;5:432.

35. Zycinska K, Wardyn KA, Zielonka TM, Demkow U, Traburzynski MS. Chronic crusting, nasal carriage of staphylococcus aureus and relapse rate in pulmonary Wegener's granulomatosis. J Physiol Pharmacol. 2008;59 Suppl 6: 825–31.

36. Popa ER, Stegeman CA, Kallenberg CG, Tervaert JW. Staphylococcus aureus and wegener's granulomatosis. Arthritis Res. 2002;4(2):77–9.

37. Niebuhr M, Gathmann M, Scharonow H, et al. Staphylococcal alpha-toxin is a strong inducer of interleukin-17 in humans. Infect Immun. 2011;79(4): 1615–22.

38. van Leeuwen EM, Remmerswaal EB, Vossen MT, et al. Emergence of a CD4 + CD28- granzyme B+, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection. J Immunol. 2004;173(3):1834–41.

39. van de Berg PJ, Yong SL, Remmerswaal EB, van Lier RA, ten Berge IJ. Cytomegalovirus-induced effector T cells cause endothelial cell damage. Clin Vaccine Immunol. 2012;19(5):772–9.